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ABSTRACT
Background: Cyclooxygenase-2 (COX-2) directs the synthesis of prostaglandins including PGE-2 linking inflammation with 
mitogenic signaling. COX-2 is also an anticancer target, however, treatment strategies have been limited by unreliable 
expression assays and by inconsistent tumor responses to COX-2 inhibition.
Methods: We analyzed the TCGA and Director’s Challenge lung cancer datasets (n = 188) and also generated an LKB1-null 
lung cancer gene signature (n = 53) to search the Broad Institute/Connectivity-MAP (C-MAP) dataset. We performed ChIP 
analyses, real-time polymerase chain reaction, immunoblotting, and drug testing of tumor cell lines (n = 8) and primary 
lung adenocarcinoma surgical resections (n = 13).
Results: We show that COX-2 is a target of the cAMP/CREB coactivator CRTC1 signaling pathway. In addition, we detected a 
correlation between LKB1 status, CRTC1 activation, and presence of glycosylated, but not inactive hypoglycosylated COX-2 
in primary lung adenocarcinoma. A search of the C-MAP drug database discovered that all high-ranking drugs positively 
associated with the LKB1-null signature are known CRTC1 activators, including forskolin and six different PGE-2 analogues. 
Somatic LKB1 mutations are present in 20.0% of lung adenocarcinomas, and we observed growth inhibition with COX-2 
inhibitors in LKB1-null lung cancer cells with activated CRTC1 as compared with LKB1-wildtype cells (NS-398, P = .002 and 
Niflumic acid, P = .006; two-tailed t test).
Conclusion: CRTC1 activation is a key event that drives the LKB1-null mRNA signature in lung cancer. We also identified 
a positive feedback LKB1/CRTC1 signaling loop for COX-2/PGE2 regulation. These data suggest a role for LKB1 status and 
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Our laboratory isolated CRTC1 (ie, MECT1/TORC1) as the onco-
genic element of a recurrent chromosomal rearrangement that 
underlies the etiology of salivary gland tumors and a rare subset 
of primary lung tumors (1–4). CRTCs were independently identi-
fied as essential LKB1/AMPK family-regulated CREB coactivators 
that: 1) control a cassette of enzymes linked with glucose/fatty 
acid metabolism (5–7), 2) mediate the ability of AMPK to regulate 
aging in C. elegans (8), and 3) are linked in genome-wide associa-
tion studies to development of esophageal cancer and Barrett’s 
esophagus (9). LKB1 mutations are among the most common 
somatic events in lung adenocarcinoma (10,11), and our pre-
vious studies detected aberrant CRTC1 activation in lung and 
esophageal cancer samples carrying LKB1-null alleles (12,13), 
suggesting a role in lung tumorigenesis. In this model, somatic 
LKB1 mutations result in hypophosphorylated CRTC1 that is 
enriched in the nucleus to activate downstream cAMP/CREB 
target genes that may directly participate in tumorigenesis (see 
Supplementary Figure  1, available online). In this manuscript, 
we have now identified CRTC1 activation as a primary event 
driving the LKB1-null mRNA signature in lung cancer and have 
detected induction of glycosylated COX-2 (ie, PTSG2) protein, 
but not the inactive hypoglycosylated species, as a specific bio-
marker in LKB1-null lung adenocarcinoma resection samples.
The related COX-1 and COX-2 products initiate the synthesis 
of potent lipid signaling messengers called prostaglandins from 
membrane-bound arachidonic acid using dual cyclooxygenase 
and peroxidase enzymatic properties (14–16). In contrast to COX-
1, the COX-2 product is not detected in most adult normal tissues 
and is selectively activated by tumor mitogens; elevated levels of 
COX-2 protein are detected in a large number of premalignant and 
malignant tissues (17). These observations have focused atten-
tion for the past two decades on COX-2 as a tumor biomarker and 
as a potential therapeutic target for cancer treatment and preven-
tion by COX-2 inhibitors such as aspirin and related nonsteroi-
dal anti-inflammatory agents (NSAIDs) (18). COX-2 inhibitors 
suppress tumor cell growth in vitro and in vivo by induction of 
apoptosis (19,20). However, despite promising preclinical results 
using tumor cell lines in vitro and xenograft mouse models in 
vivo, there have been inconsistent data supporting COX-2 as a 
tumor biomarker and as the etiologic target for the cancer pre-
vention activity of aspirin and NSAIDs (21). In this manuscript, 
we have identified a positive feedback loop between CRTC/COX-2/
PGE2/cAMP and have linked LKB1 loss and CRTC1 activation with 
induction of glycosylated COX-2 protein and preferential sensitiv-
ity to COX-2 inhibition. These data suggest a more focused strat-
egy for future cancer treatment and prevention clinical trials.
Methods
Plasmids
LKB1 and CRTC1 plasmids were previously described (12). The 
pLKO.1 lentiviral LKB1 shRNA and CRTC1 shRNA constructs were 
obtained from Open Biosystems (Huntsville, AL). The COX-2 pro-
moter plasmid was a gift of Dr. Curtis C. Harris (National Cancer 
Institute, National Institutes of Health, Bethesda, MD). Retroviral 
and lentiviral vectors were transfected with helper plasmids into 
HEK293 cells using FUGENE 6 reagent (Roche Applied Science, 
Indianapolis, IN). Cell clones with stable expression were main-
tained in puromycin (Sigma, St Louis, MO) selection.
Tumor Cells
Lung and esophageal cancer cell lines (A549, H2126, H23, H460, 
A427, H157, H2122, H1819, H2087, H358, H2009, H322, H522, H3123, 
TE4, and KYSE-70) were cultured in RPMI 1640 medium supple-
mented with 10% FBS and antibiotics (Life Technologies, Long 
Island, NY). Lung adenocarcinoma biopsy samples (n = 13) were 
collected from the Moffitt Cancer Center Program using institu-
tional review board–approved protocols with signed informed 
consent, snap frozen within 15 minutes, and analyzed as deiden-
tified samples using approved Material Transfer Agreement with 
the University of Florida. Proteins extracts were lysed in RIPA 
buffer (Boston Bioproducts, Ashland, MA) and subjected to immu-
noblotting as described in the Supplementary Methods (available 
online).
Reagents and Antibodies
Mouse monoclonal anti-LKB1 and goat polyclonal antibodies 
anti-COX-2 antibodies were purchased from Santa Cruz (Santa 
Cruz, CA). Rabbit polyclonal anti-CRTC1 was purchased from 
Rockland Immunochemicals (Gilbertsville, PA).
Luciferase Assays
COX-2 promoter assays were performed with the dual-luciferase 
assay kit (Promega Corporation, Madison, WI) 48 hours after 
transfected with the indicated constructs. Normalized promoter 
activity represents average values from triplicate determina-
tions with SD values.
ChIP Assay
The protocol was adapted from Chen et al. (22). Briefly, cells were 
fixed with 1% formaldehyde for 15 minutes, harvested, and rinsed 
2× with 1× PBS. The cell pellet was sonicated, and crosslinked DNA 
fragments were enriched by immunoprecipitation with anti-CRTC1 
antibody or rabbit immunoglobulin G (IgG) as control. The purified 
DNA is subjected to real-time (RT) polymerase chain reaction (PCR) 
amplification using 5’ COX-2 promoter or 3’UTR primers. 5’ COX-
2 promoter: forward 5′- CCCCCACCGGGCTTACGCA-3′; Reverse 
5′- TGCTCCTGACGCTCACTGCAA-3′. COX-2 3’UTR: forward 5′- 
GGTAAACCTCAGCTCAGGACTGCTA -3′; Reverse 5′-TCTCTGAGGC 
ACTAGCCTCTTTGC-3′.
RT-PCR Analysis
Total RNA was isolated with TRIzol (Invitrogen, Grand Island, 
NY), and 2 μg processed with the High-Capacity cDNA Reverse 
Transcription Kits (Applied Biosystems, Grand Island, NY) and 
TaqMan Fast Universal PCR Master Mix (Applied Biosystems, 
Grand Island, NY). Quantitative real-time PCR (qRT-PCR) was 
carried out using a 7900 HT Fast (Applied Biosystems, Grand 
Island, NY) system, and expression of target genes mRNA rela-
tive to 18s rRNA was calculated.
Immunofluorescence
Cells were washed with PBS, fixed with 4% formaldehyde for 10 
minutes at 37°C, permeabilized with 0.5% Triton X-100 for five 
minutes at room temperature, and then blocked with 3% BSA 
overnight at 4°C. After washing with PBS, cells were incubated 
with primary antibody (1:1000 dilution) in 1% BSA for one hour 
at room temperature and then secondary antibody (1:10,000 
dilution) conjugated to Alexa Fluor 594 for one hour at room 
temperature. Nuclei were stained with DAPI in the Vectashield 
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Wound-Healing Scratch Assay
Cells were grown to confluence and wounds were created by 
manually scraping the cell monolayer with a 200 ul pipette 
tip. Cells were washed twice in PBS for and photographed at 0 
hours and 48 hours as indicated. Cell migration was evaluated 
by measuring the width of the wound at the identical position.
MTS Assay
Lung cancer cells (1 × 103 cells/well) were cultured in 96-well plates 
(Corning, NY) with medium plus DMSO or in the presence of COX-2 
inhibitors, NS-398 or Niflumic Acid (Cayman Chemical Company, 
Ann Arbor, MI). Plates were incubated (5% CO2, 37°C) for 72 hours. 
Cell proliferation was measured using MTS reagent as recom-
mended by the manufacturer (Promega Corporation, Madison, WI).
Generation of LKB1 Mutation Signature
Cell-line gene expression and metadata (n  =  53 lung can-
cer cell lines) was obtained from ArrayExpress (23) accession 
E-MTAB-783, supplemented with additional data from the 
Sanger Cell Line Project (http://www.broadinstitute.org/cgi-bin/
cancer/datasets.cgi). CEL files were normalized using IRON (24) 
against the median sample. Histology and site of origin was 
conformed, and several misannotated cell lines, identified as 
outliers through principle component analysis (PCA), were cor-
rected for histology and site of origin where supported by litera-
ture (A4-Fuk, MDA-MB-435, NCI-H1155, NCI-H1299, NCI-H1770, 
NCI-H810, SK-NEP-1). Large differences in gene expression were 
observed because of the batch effect (Affy_batch in the Sanger/
Broad metadata) and corrected with COMBAT (25), using a con-
formed combination of site of origin and histology as the covari-
able. LKB1 mutational status for non–small cell lung cancer 
cell lines was curated from the literature (Luc Girard, personal 
communication) and confirmed in selected cases by immuno-
blotting. See the Supplementary Methods  (available online) for 
further details.
Generation of Drug-Response Signatures from 
Connectivity Map Data
Gene expression CEL file data was downloaded from the 
Connectivity Map (26) (CMAP) website (http://www.broadinsti-
tute.org/cmap/), consisting of 7056 CEL files covering 1309 com-
pounds. See the Supplementary Methods  (available online) for 
further details.
Searching CMAP Drug-Response Signatures Against 
LKB1 Signature
The LKB1 signature was compared against the CMAP drug-
response signatures. Signature probesets not present in the 
CMAP drug-response dataset were removed prior to searching. 
For each compound, the Tanimoto Similarity (27) and Fisher’s 
exact test (Poverlap) were calculated for the overlap of the LKB1 and 
compound signatures. Additionally, % overlap was calculated as 
100 * (# overlap/min [size of compound signature], size of LKB1 
signature). To further score the agreement of signs between the 
overlapping probesets, the quadrant count ratio ([# agree in sign 
- # opposite in sign]/# overlap) was calculated, as well as the P 
value of the sign agreement, Psigns, assuming a two-sided bino-
mial distribution. Compounds with three or more overlapping 
probesets, 5% or greater overlap, Poverlap less than .05, Psigns less 
than .05, and quadrant count ratio over 0.5 were considered to 
be statistically significant compound hits. Final overlap score 
was defined as: % overlap * # overlap * Tanimoto Similarity * 
quadrant count ratio * -log2(Poverlap) * -log2(Psigns).
Statistical Analysis
Experimental data were expressed as the mean ± SD. Differences 
were considered statistically significant at P less than .05 using 
a two-tailed t test. Statistical analyses were performed using 
Graphpad Prism software version 5.00 (Graphpad Software, 
Inc., CA).
Other materials and methods are described in the 
Supplementary Methods  (available online).
Results
Effect of CRTC1 Activation in LKB1-Null Cells on 
COX-2 Expression
To study downstream CRTC1/cAMP/CREB target genes in lung 
cancer, we analyzed the collection of 2516 predicted CREB tar-
get genes (28) on the Affymetrix HG-U133A platform using the 
Director’s Challenge lung adenocarcinoma and TCGA squamous 
cell carcinoma public datasets (29). We selected lung cancer 
because we show that endogenous CRTC1 migrates predomi-
nantly as an aberrantly activated underphosphorylated spe-
cies (Figure  1A) that is enriched in the nucleus in LKB1-null 
lung tumor cell lines (Supplementary Figure 2, available online). 
Analysis of lung adenocarcinoma (Figure 1B) and lung squamous 
cell carcinoma (Figure 1C) datasets (n = 188) identified COX-2 as a 
CREB-regulated biomarker inversely correlated with LKB1 status.
To confirm that COX-2 promoter activity was augmented 
in LKB1-null cells, we transfected the pGL3-endogenous-
COX-2-promoter luciferase reporter into lung tumor lines and 
detected increased promoter activity in LKB1-null as compared 
with wildtype (wt) cells (Figure  1D). We also tested the forced 
expression of wt LKB1 in LKB1-null A549 cells and observed 
repression of COX-2 protein associated with CRTC1 hyperphos-
phorylation (Figure  2A). Reduced COX-2 mRNA was observed 
in all four LKB1-null tumor cell lines following ectopic expres-
sion of wt LKB1 as compared with vector control (Figure  2B). 
Conversely, shRNA-mediated depletion in LKB1-wt cells (H2087) 
resulted in a subtle downward shift in CRTC1 mobility and 
induction of COX-2 protein (Figure 2C) and mRNA levels in each 
of four different LKB1-wt lung cancer lines (Figure 2D). Similar 
findings were observed in esophageal cancer lines with defined 
LKB1 status (Supplementary Figure 3, available online). Finally, 
we confirmed regulation of COX-2 promoter activity following 
ectopic LKB1 expression (P = .02, two-tailed t test) (Figure 2E) or 
shRNA depletion of endogenous LKB1 (P = .04, two-tailed t test) 
(Figure 2F) using the pGL3-COX-2-promoter luciferase reporter.
To test if LKB1-regulated CRTC1 can directly activate COX-2, we 
first showed coexpression of CRTC1 and COX-2 protein in each of 
16 different adult mouse tissues tested by protein immunoblotting 
(Supplementary Figure 4, available online). Since human tumors 
express abundant CRTC1, we selected NIH3T3 cells with low endog-
enous CRTC1 and COX-2 levels and transfected either wt CRTC1 
or a constitutively activated S151A CRTC1 that cannot undergo 
LKB1/AMPK-mediated phosphorylation (8,12,30). Levels of ectopic 
CRTC1 were comparable with endogenous steady-state CRTC1 in 
human tumor cells and we observed a nine-fold and more than 
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or activated S151A CRTC1, respectively (Figure 3A). Cotransfection 
of CRTC1 shRNA blocked both CRTC1 expression and COX-2 induc-
tion. In addition, wt and S151A CRTC1 led to five-fold and 14-fold 
induction of COX-2 promoter activity, respectively (Figure  3B). 
Finally, chromatin immunoprecipitation (ChIP) analysis, using a 
highly specific anti-CRTC1 antibody (12), demonstrated binding 
of endogenous CRTC1 at the conserved 5’ promoter CRE element 
with 10-fold enrichment as compared with an IgG control or to 
ChIP from the 3’ untranslated COX-2 region (Figure 3C).
 In summary, we demonstrate that activated CRTC1 enhances 
endogenous COX-2 expression in LKB1-null cells. Since PGE2 is 
both the product of COX-2 and can activate COX-2 expression in 
tumor cells (31,32), these data propose a novel positive feedback 
loop that is deregulated by loss of LKB1 and mediated by activa-
tion of CRTC1 (Figure 3D).
CRTC1 Activation and the LKB1-Null Gene Signature
We validated the LKB1 status and obtained global gene expres-
sion data in 53 lung cancer cell lines to define an LKB1-null 
mRNA signature that was used to screen the Broad Institute 
Connectivity Map (CMAP) (26) for potential drug compounds 
that induce this LKB1 signature. Only four outlier LKB1-wt lung 
tumor cell lines clustered within the LKB1-null signature, includ-
ing H292 (Figure 4A, depicted by an arrow), which expresses a 
constitutively activated CRTC1 fusion oncogene required for 
tumorigenicity (1,33). This suggests an association of activated 
CRTC1 with expression of an LKB1-null signature. We confirmed 
this hypothesis by observing that each top-scoring compound 
from the CMAP database that was positively correlated with the 
LKB1-null signature represents a drug known to activate CRTC1 
(two separate P value tests for each compound along with other 
measures of overlap and association were used to generate an 
overall composite score shown in Table 1; the statistical tests, 
measures of overlap and association, and the cutoffs used for 
significance are detailed in the Supplementary Methods, avail-
able online). For example, the top-scoring drug was colforsin, a 
water-soluble forskolin analogue that serves as the prototype for 
CRTC1 activation (see Supplementary Figure 2, available online) 
(6). In addition, multiple beta-adrenergic receptor agonists (34) 
and prostaglandin/PGE2 analogues (35) known to activate cAMP/
CRTC1 were identified (Figure  4B). These data support a posi-
tive feedback loop, amplified by loss of LKB1, where the COX-2 
product, PGE2, binds cognate EP receptors triggering cAMP/PKA 
activation that sustains CRTC1 dephosphorylation and further 
COX-2 activation (Figure 3D). In summary, these discoveries sug-
gest that CRTC1 activation drives the LKB1-null mRNA signa-
ture and plays a critical role to mediate tumorigenic signaling 
in LKB1-null cancer cells. In addition, as predicted by clustering 
of the H292 cell line with the LKB1-null signature, we confirmed 
that activated CRTC1-MAML2 induced COX-2 protein expression 
(Supplementary Figure 5, available online).
Figure 1. LKB1-CRTC1 circuit regulates COX-2 in lung cancer cells. A) Protein immunoblot of endogenous CRTC1 in lung cancer lines. B) Heatmap generated from lung 
adenocarcinoma caArray dataset (left panel). Total of 100 lung adenocarcinoma samples (top 50 and bottom 50 samples on basis of COX-2 expression) were identified 
and subjected to analysis. One hundred fifty-one differentially expressed CREB target genes (39) (P < .05 and |fold change|>1.5) were identified concordant with COX-2 
expression in lung adenocarcinoma (see Supplementary Methods, available online, steps for further details; see Supplementary Table 1, available online, for list of dif-
ferentially expressed gene targets) (right panel). The top and bottom quartile samples (n = 72) were selected for analysis on basis of HighCOX2/LowLKB1 or LowCOX2/
HighLKB1 expression. Five hundred and five probe sets (P < .05 and |fold change|>1.5) were identified inversely correlated with LKB1. C) heatmap was generated from the 
TCGA lung squamous cell cancer dataset (left panel). Total of 88 samples (either High COX-2 or Low COX-2) were selected for analysis. One hundred and nineteen CREB 
target Probe sets (P < .05 and |fold change|>1.5) were identified (right panel). Total of 56 samples (either High COX-2-Low LKB1 or Low COX-2-High LKB1) were selected for 
analysis. Two hundred and eight CREB target Probe sets (P < .05 and |fold change|>1.5) were identified (see Supplementary Methods, available online, for further details). 
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Glycosylated COX-2 as a Specific Biomarker for 
LKB1-Null Lung Cancer
COX-2 is differentially modified by N-glycosylation at Asn53, 
Asn130, Asn396, and Asn 580 sites (Figure 5A) (14,36). There are no 
previously published reports that discriminate glycosylated and 
basal COX-2 protein in lung tumor samples. Since LKB1/CRTC1 
activates pathways associated with anabolic glucose metabolism 
(5) and since near-maximal N-glycosylation is required for COX-2 
enzyme activity (36), we hypothesized that detection of glyco-
sylated COX-2 could be a key biomarker for studying LKB1/CRTC1 
activation in lung adenocarcinoma. In addition, we hypothesized 
that the failure of immunohistochemical assays to discriminate 
between unglycosylated and glycosylated COX-2 may explain the 
inconsistent role of COX-2 as a tumor biomarker and as a predic-
tor for COX-2 inhibition in preclinical studies.
To test these hypotheses, lung adenocarcinoma surgical 
resections were subjected to immunoblot analysis for LKB1 
and COX-2 expression. Despite presence of contaminating nor-
mal tissue, we were able to infer LKB1 status by scoring pro-
tein levels compared with ß-actin controls (Figure 5B). We also 
obtained LKB1 exon sequencing to confirm immunoblot findings 
in selected cases. We observed the slower mobility 72 of 74 kDa 
COX-2 glycoforms in LKB1-null samples, while LKB1-wt samples 
were enriched for the faster migrating basal, 66–70 kDa species 
(Figure 5B). Similar data were observed in two primary esopha-
geal cancer biopsy samples with matched adjacent normal tis-
sue (Supplementary Figure 6, available online).
To confirm these findings, we assessed the effect of tunica-
mycin to block N-glycosylation in lung tumor lines (Figure 5C). 
A549 LKB1-null and H2087 LKB1-wt cells were engineered to 
stably express vector control, LKB1, or LKB1-shRNA, respec-
tively, in the presence or absence of tunicamycin. As expected, 
tunicamycin collapsed the slower mobility COX-2 species to the 
enzymatically inactive, hypoglycosylated 66, and 70 kDa spe-
cies. Unexpectedly, glycosylated 72–74 kDa COX-2 species were 
detected in a nuclear membrane compartment that fractionated 
with the nuclear extract as compared with the hypoglycosylated 
species that fractionated to the cytoplasm (Figure 5D), confirm-
ing biological distinctions between differentially glycosylated 
COX-2 species.
Effect of LKB1 Status on Preferentially Sensitivity to 
COX-2 Inhibition in Lung Cancer
We tested the clinical implications of these findings by first 
investigating all published preclinical reports on the growth 
Figure 2. LKB1 regulates COX-2 in lung cancer cells through CRTC1. A) Protein immunoblot with indicated antibodies in A549 LKB1-null tumor cells. B) Quantitative real-
time polymerase chain reaction analyses in LKB1-null tumor cell lines were normalized with 18S rRNA. Indicated cells were tested after forced expression with LKB1 or 
empty vector for 48 hours. C and D) Similar analyses as panels (A) and (B), except for use of LKB1-wt lung cancer cells following LKB1 shRNA depletion. E) COX-2 promoter-
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Figure 3. CRTC1 directly regulates COX-2 and predicts a positive feedback loop deregulated following LKB1 loss. A) Protein immunoblot showing fold induction 
of COX-2 following ectopic expression of wt or constitutively activated S151A CRTC1. B) COX-2 promoter luciferase induction following ectopic expression of 
wt or S151A CRTC1. C) ChIP assay of CRTC1 binding to the 5’ COX2 promoter in lung cancer cells. P = .0016 vs IgG control for the real-time polymerase chain 
reaction analysis using the primers flanking the COX-2 promoter (two-tailed t test). The conserved CREB binding site (CRE) upstream of the TATA element in 
the COX-2 promoter is depicted. D) Illustration showing a new CRTC1 → COX-2 → PGE2 → cAMP → CRTC1 signaling loop that is normally restrained by wildtype 
LKB1 → AMPK/SIK1/2/MARK2 signaling. LKB1 is the master upstream regulator for AMPK-related kinases that phosphorylate and repress CRTC1 transcriptional 
activation via cytoplasmic sequestration. PGE2 (synthesized by COX-2), forskolin, and ß-adrenergic receptor agonists are known cAMP/CRTC1 activators and are 
depicted in red.
Figure 4. CRTC1 activation drives the LKB1-null gene signature. A) Principle component analysis of LKB1-null gene expression signature. LKB1-mutant lung cancer cell 
lines (red) completely separate from LKB1-wt cell lines (blue) along the first principle component. Four outlier LKB1-wt cell lines (H292, H2170, H2342, EKVX) exhibited 
an LKB1-null gene expression pattern (yellow). These cell lines were identified and omitted prior to signature generation. Two EKVX replicates were included for quality 
control and exhibit high reproducibility. The outlier H292 cell line (arrow) expresses the endogenous activated CRTC1 fusion oncogene that is required for sustained 
tumor cell growth (1,31). B) The indicated top scoring drugs identified in the C-MAP screen that drive the LKB1-null signature are known cAMP/CRTC1 activators. 
Custom software, metadata tables, and CMAP differentially expressed gene lists used in the CMAP and E-MTAB-783 analyses (see Supplementary Methods, available 
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inhibitory effects of COX-2 inhibitors. We performed a PubMed 
search with the terms “COX-2 or PTGS2 inhibitor” and “lung 
cancer” and identified 52 publications over the past decade that 
showed a striking enrichment for growth inhibition in LKB1-null 
tumor lines. Although only 20% of non–small cell lung cancers 
are LKB1-null, 48 of 52 publications (92.3%) that assessed pre-
clinical testing of COX-2 inhibitors in lung cancer in vivo or in 
vitro used the LKB1-null cell lines A549, H460, H23, H157, A427, 
Table 2. Preclinical studies with COX-2 inhibitors in human lung cancer xenograft models1999-2014
Cell Lines
Reference URLLKB1 null LKB1 wt
A549 (Zhang H, Li Z, Wang K 2014) http://www.ncbi.nlm.nih.gov/pubmed/24549815
A549 (Zhang S et al. 2014) http://www.ncbi.nlm.nih.gov/pubmed/24374173
A549 (Klenke et al. 2011) http://www.ncbi.nlm.nih.gov/pubmed/21234531
A549 H1299 (Moody et al. 2010) http://www.ncbi.nlm.nih.gov/pubmed/19628293
A549 (Kim et al. 2009) http://www.ncbi.nlm.nih.gov/pubmed/19360361
A549 (Grimes et al. 2006) http://www.ncbi.nlm.nih.gov/pubmed/16969492
A549 (Fulzele et al. 2006) http://www.ncbi.nlm.nih.gov/pubmed/16902813
A549 (Backhus et al. 2006) http://www.ncbi.nlm.nih.gov/pubmed/16872953
A549 (Shaik et al. 2006) http://www.ncbi.nlm.nih.gov/pubmed/16052515
A549 (Sievers et al. 2005) http://www.ncbi.nlm.nih.gov/pubmed/15942563
A549 (Tuccillo et al. 2005) http://www.ncbi.nlm.nih.gov/pubmed/15709198
A549 (Shaik et al. 2004) http://www.ncbi.nlm.nih.gov/pubmed/14977856
A549 (Liu et al. 2003) http://www.ncbi.nlm.nih.gov/pubmed/12902866
ACC-LC-319 (Hida et al. 2002) http://www.ncbi.nlm.nih.gov/pubmed/12114451
H460 (Pyo et al. 2001) http://www.ncbi.nlm.nih.gov/pubmed/11595687
Figure 5. Glycosylated COX-2 linked to LKB1 status in lung adenocarcinoma biopsy samples. A) Location of the 4 N-linked glycosylation sites of COX-2 and correspond-
ing kDa (36). B) Protein immunoblot analysis from 13 fresh frozen lung primary lung adenocarcinoma resections using indicated antibodies. LKB1-null status (indicated 
with an asterisk) was inferred from relative LKB1 expression and direct gene resequencing. C) Protein immunoblot analyses of LKB1-null (A549) or wt (H2087) lung 
cancer cell lines in the presence or absence of tunicamycin after forced LKB1 expression or shRNA depletion, respectively. D) Protein immunoblots with whole cell 
lysates (W), cytoplasmic (C), or nuclear (N) fractions from the indicated lung cancer cells using the indicated antibodies, including HDAC1, enriched in the nucleus, and 
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Figure 6. LKB1-null lung cancer cells are preferentially sensitive to COX-2 inhibition. A) LKB1-null H23 and LKB1-wt H322 cells were incubated with vehicle (DMSO) or 
Niflumic Acid at indicated µM doses. After 72 hours, MTS-based cell viability was determined. B) Scratch assay showing that NS-398 preferentially inhibits cell mobil-
ity in LKB1-null tumor cells. C) Seven different lung cancer cells with indicated LKB1 status were treated with either NS-398 (50 μM), P = .002 LKB1 null vs LKB1 wt or 
Niflumic Acid (300 μM), P = .006 LKB1 null vs LKB1 wt for 72 hours. MTS-based cell viability was determined as the mean of three independent experiments. D) Forced 
expression of LKB1 in A549 cells confers resistance to both COX-2 inhibitor agents using an MTS-based cell assay (72-hour incubation with either 100 μM NS-398 (left) 
P = .05 or 400 μM Niflumic Acid (right) P = .02. E) shRNA depletion of LKB1 in H2087 cells confers enhanced sensitivity to both COX-2 inhibitors under the same condi-
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or H2126. Fourteen of 15 publications (93.3%) showed tumor 
growth inhibition in LKB1-null lung cancer cells using in vivo 
mouse xenograft models (see Table 2), and 34 of 37 (91.9%) pub-
lished reports showed tumor inhibition in LKB1-null lung can-
cer cells using in vitro assays (Supplementary Table 2, available 
online).
We then tested H23 (LKB1-null) or H322 (LKB1-wt) lung can-
cer cells with either the COX-2 inhibitors NS-398 or Niflumic 
Acid (Figure  6A) and observed enhanced cell killing in the 
LKB1-null tumor samples using clinically achievable in vivo 
doses (Supplementary Table 3, available online). The effects of 
COX-2 inhibition on tumor cell migration were also assessed 
by scratch assays, which demonstrated enhanced inhibition of 
LKB1-null cell migration (Figure 6B). We extended these observa-
tions by testing seven different lung cancer cell lines using both 
COX-2 inhibitors and observed enhanced efficacy in LKB1-null 
cells (P = .002 for NS-398; P = .006 for Niflumic Acid) (Figure 6C). 
Finally, we validated these findings by observing loss of drug 
sensitivity to both COX-2 inhibitors after engineering A549 cells 
to express wt LKB1 (P =.05 for NS-398; P =.02 for Niflumic Acid) 
(Figure 6D). Conversely, we observed enhanced tumor cell inhi-
bition with either Niflumic acid or NS-398 after shRNA depletion 
of LKB1 in H2087 cells (P =.03 for NS-398; P =.02 for Niflumic Acid) 
(Figure 6E).
To further confirm these data, we also tested tumor growth 
inhibition following COX-2 inhibition either by COX-2 inhibi-
tor or shRNA depletion using a colony formation assay on 
eight lung cancer cell lines (four LKB1-null and four wt) (see 
Supplementary Figure 7, available online) and also using an in 
vivo mouse xenograft models (P = .02 with n = 12 mice and three 
mice for each treatment group) (see Supplementary Figure  8, 
available online). In summary, both assays detected preferential 
tumor growth inhibition in LKB1-null as compared with LKB1-
wildtype lung tumor cells.
Discussion
These data raise several important points. First, because LKB1 
signaling has the potential to impact many different phenotypes 
linked to alterations in cell polarity, cell invasion and motility, 
cell cycle regulation, and anabolic metabolism, there has been 
uncertainty in defining key signaling pathway(s) that underlie 
lung tumorigenesis following somatic mutational events (10). 
Our discovery that CRTC1 activators, including forskolin, PGE 
analogues, and beta-adrenergic agonist, drive the LKB1-null 
mRNA signature in lung cancer samples has provided a new 
understanding connecting CRTC/CREB coactivation with aber-
rant AMPK/SIK1/2 signaling as a critical event underlying this 
subset of lung cancer. Second, we identified a positive PGE2 → 
CRTC1/COX-2 → PGE2 feedback loop deregulated by loss of LKB1. 
The identification of COX-2 as a target for CRTC1 activation also 
helps explain earlier observations that gastrointestinal polyps 
in a Peutz-Jeghers LKB1-null mouse model are preferentially 
sensitive to tumor inhibition by COX-2 inhibitors (37). Finally, we 
identified induction of glycosylated COX-2 species as a predic-
tive biomarker for LKB1-null lung adenocarcinoma samples that 
suggests limitations for the routine use of COX-2 immunohisto-
chemical assays that do not discriminate between basal inactive 
COX-2. Study limitations for this analysis include the require-
ment for assays on additional tumor samples to validate these 
results and to determine if LKB1 loss acts jointly with other 
cooperating events such as KRAS mutations.
More recently, LKB1-null tumor cells have also been cor-
related with enhanced sensitivity in vivo to the mitochondrial 
inhibitor and AMPK activator, phenformin (38), although the 
mechanism for this effect is still undefined. In addition, a 
high-throughput screen using siRNA/synthetic small mol-
ecules identified sensitivity to depletion of COPI subunits in 
LKB1-null lung cancer cells (39), suggesting a possible role 
through maintenance and organization of Golgi machinery 
including glycosylation pathways (40). In summary, the CREB 
coactivator CRTC family links LKB1 with COX-2 activation and 
provides a new framework for selecting patients for COX-2 
inhibition.
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